Invasive fungal infections, such as COVID-19 associated pulmonary aspergillosis and mucormycosis, have become serious complications during the COVID-19 pandemic. The global spread of the multidrug-resistant Candida auris has highlighted the challenges faced by health systems in combating fungal infections. Despite the severity of these infections, research funding and diagnostic and therapeutic options have been lacking. The World Health Organization (WHO) recently published a fungal priority pathogens list to address neglected pathogens. Fortunately, new antifungal drugs like rezafungin, ibrexafungerp, olorofim, and fosmanogepix are in advanced trial stages or have been approved by regulatory bodies. Rezafungin is a new echinocandin with a long half-life that allows for less frequent dosing. It has been approved by the US FDA for the treatment of candidaemia and invasive candidiasis. Ibrexafungerp, the first non-azole agent approved by the FDA, has shown promising results in treating vaginal yeast infections and urinary tract infections. Olorofim, a novel antifungal drug, has demonstrated efficacy against several clinically important fungi but requires further trials for conclusive evidence. Fosmanogepix, with broad-spectrum activity, has shown positive survival rates in patients with invasive candidaemia caused by Candida auris. These new antifungal drugs offer hope for replenishing therapeutic options for invasive fungal infections. However, their effectiveness must be combined with investments in diagnostic tools and surveillance to effectively combat pathogenic fungi. With continued research and development, these drugs could mark a new chapter in the fight against fungal infections.

To know more: About the original article click here.